The EMA’s CHMP adopted a positive opinion, recommending the granting of a conditional marketing authorisation for Kayshild (semaglutide), intended for the treatment of adults with non-cirrhotic metabolic dysfunction-associated… read more.
A new study from Adelaide University is turning a spotlight on those tablet versions, finding that the absorption-enhancing ingredient salcaprozate sodium (SNAC) may have measurable adverse biological effects for the gut and… read more.
Researchers from a large international study report that obesity significantly increases the risk of hospitalization and death from many infectious diseases, including flu, COVID-19, pneumonia, gastroenteritis, urinary tract… read more.
Novo Nordisk announced that the FDA has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and… read more.
An estimated 1.6 million adults in England, Wales and Scotland used drugs such as Wegovy and Mounjaro to help lose weight between early 2024 and early 2025, according… read more.
Researchers report that ending the use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss is associated with weight regain and a reversal of heart health markers. The… read more.
When Americans begin taking appetite-suppressing drugs like Ozempic and Wegovy, the changes extend well beyond the bathroom scale. According to new Cornell University research, the medications are associated… read more.
Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used… read more.
The EU drug watchdog, the European Medicines Agency (EMA), has launched a partnership with social media influencers to promote the safe use of GLP-1 receptor agonists. The #HealthNotHype… read more.
In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their pregnancy tended to gain… read more.
Around two-thirds of pregnancies have weight gain that is more or less than recommended and is associated with complications such as preterm birth, large birth weight, and admission… read more.
Orforglipron , an investigative and oral GLP-1 drug, appears to enable adults with obesity and Type 2 diabetes to achieve significantly more weight loss and improvement in blood… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
